Uvamin Retard is used to help manage the uncomfortable symptoms associated with infections of the urinary tract, a common category of conditions. The active ingredient is used in clinical scenarios for both treating an ongoing condition and for infection prevention.

This medicine is indicated for acute and chronic conditions, including infections of the bladder (cystitis) and renal pelvis, as well as for prophylaxis (prevention) during diagnostic examinations or after surgical procedures on the urinary tract system. The main benefit patients may receive is the relief of symptoms tied to the infection.

As is customary for similar prescription medications, a healthcare professional will determine the appropriate clinical use.

“This formulation is used to provide therapeutic benefit in specific urinary tract conditions.”

---

Quick Fact: Relief for Urinary Discomfort

The eligibility for using Uvamin Retard (nitrofurantoin prolonged-release) is strictly defined by regulatory authorities based on age, physiological status, and underlying medical conditions. This formulation is typically allowed for adults and adolescents aged 12 and above.

Populations for Whom Use is Contraindicated

Use is absolutely prohibited in several defined populations due to risk of inefficacy or toxicity, including:

• Patients with known hypersensitivity to nitrofurantoin or any nitrofuran derivatives.
• Individuals with severe renal dysfunction, defined by official labels as a creatinine clearance ( CrCl) under 60 mL/min or an estimated Glomerular Filtration Rate ( eGFR) under 45 mL/min.
• Patients with acute porphyria, pulmonary fibrosis, or specific neurological conditions like polyneuropathy.
• Infants under one month (or three months, regionally).
• Pregnant patients at term (near labor/delivery) due to the risk of hemolytic anemia in the newborn.
• Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Populations Requiring Conditional or Restricted Use

• The prolonged-release capsule is not recommended for children under 12 years of age.
• Older adults (geriatric population) may use the medicine provided their renal function is closely monitored and remains above the contraindication threshold.
• Use during the first six months of pregnancy is restricted and should be used only if clearly necessary.

Interactions with other medicines and products

This section outlines interaction patterns for Uvamin Retard (Nitrofurantoin) as documented in official government regulatory information. These interactions are categorized based on their effect on the drug's exposure, clearance, and antibacterial activity.

Impact on Drug Exposure and Clearance

Co-administration with uricosuric agents such as Probenecid or Sulphinpyrazone causes a documented pharmacokinetic interaction. These agents inhibit the renal tubular secretion of nitrofurantoin, resulting in two simultaneous effects: an increase in systemic serum levels (toxicity risk) and a decrease in the urinary concentration (reducing antibacterial efficacy at the site of action). For patients with significant renal impairment, the impaired excretion is formally noted to increase the risk of toxicity due to systemic accumulation. Nitrofurantoin is also noted to lower the plasma concentrations of the co-administered anti-epileptic agent phenytoin.

Absorption, Timing, and Efficacy Interactions

Magnesium trisilicate antacids are documented to reduce the absorption of Uvamin Retard. Official labeling requires a timing separation rule: these antacids must be administered at least one hour later. Conversely, medicines like Propantheline may increase the urinary concentration of Uvamin Retard by improving absorption. The antibacterial effect is decreased when co-administered with urine-alkalizing agents (e.g., Sodium Bicarbonate or Carbonic Anhydrase Inhibitors). Nitrofurantoin may also reduce the effectiveness of oestrogen-containing oral contraceptives and lead to the inactivation of the Oral Typhoid Vaccine.

Activation by Bacterial Flavoproteins

The mechanism of action begins with a highly selective enzymatic reduction process occurring within the bacterial cell. The active ingredient, a prodrug, is chemically modified by bacterial enzymes called nitroreductases. This mechanism is dependent on the target cell's internal machinery, allowing the lethal molecular action to be selectively focused on the invading pathogen.

Irreversible Multi-Target Cytotoxicity

The reduced form of the molecule generates highly reactive intermediates that function as broad-spectrum cytotoxic agents. These intermediates simultaneously attack multiple, essential bacterial components, including DNA, RNA, ribosomes, and core metabolic enzymes. This immediate, multi-site damage exceeds the cell's capacity for repair, leading directly to the bactericidal effect and limiting the opportunity for bacterial adaptation and resulting resistance development.

Mechanism Constraints and Selectivity

The efficacy of this mechanism is intrinsically linked to the drug's necessity to achieve high local concentrations, which occurs primarily in the urinary tract. This local confinement allows the cytotoxic mechanism to be deployed effectively at the site of bacterial colonization. Furthermore, the multi-target, enzyme-dependent action is the physiological basis for the low rates of acquired resistance.

How to Use Uvamin Retard

This section describes the administration guidelines for Uvamin Retard (nitrofurantoin prolonged-release capsules), detailing the manner in which the medicine is administered.

---

Administration Scope and Regimen

Uvamin Retard is intended for oral administration as a prolonged-release hard capsule. The standard dosing schedule for treating acute urinary tract infections (UTIs) is 100 mg per dose, to be taken every 12 hours (twice daily) for a typical course duration of five to seven days. In cases of long-term suppressive therapy, a lower dose, such as 50 mg to 100 mg, is generally used once daily.

---

Administration Conditions and Handling

To optimize its absorption and improve gastrointestinal tolerance, the capsule must be administered with food or milk. Due to the specialized prolonged-release design, the capsule must be swallowed whole and must not be crushed, opened, or chewed. If a dose is missed, it should be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be omitted.

---

Population-Specific Use

Age and Renal Function are critical factors governing the use of this medication. The prolonged-release formulation is indicated for individuals 12 years of age and older at the adult dosage. Furthermore, its use is contraindicated in patients with significantly impaired renal function, typically defined as a Creatinine Clearance (CrCl) of less than 60 mL/minute.

Research Evidence: Overview of Clinical Studies

---

Evidence for Use in Acute, Uncomplicated Urinary Tract Infections (Cystitis)

Research exploring the use of the active ingredient, Nitrofurantoin, for acute uncomplicated infections of the lower urinary tract has consisted primarily of Randomized Controlled Trials (RCTs). These studies were used to measure specific outcomes related to both physical discomfort and the presence of bacteria. Researchers examined endpoints such as clinical resolution, which monitors how a patient’s symptoms evolved, and bacteriological response, which is measured by the change in the infecting bacteria count in laboratory cultures.

Studies were designed to examine patterns observed when compared to other study groups, including those receiving standard treatments or no active treatment. Data show patterns related to the measured clinical resolution and the rate of bacteriological response, often suggesting that patterns measured were similar to those observed in other study groups. However, certainty remains low regarding the efficacy of very short-course therapy (such as a 3-day regimen) for all types of susceptible organisms due to limited research.

---

Evidence for Use in Preventing Recurrent Urinary Tract Infections (Prophylaxis)

The drug was studied for use in patients with recurrent UTIs through long-term Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies explored outcomes such as the rate of UTI recurrence and the time elapsed until the first recurrence. Studies monitored responses over defined time intervals, comparing the continuous use of the drug against other preventative methods.

Findings from these trials described patterns where the frequency of recurrence measured during active treatment was less than that observed in study groups receiving placebo or no preventative treatment. Research highlights that the measured frequency of recurrence was generally similar to patterns observed when using other common antibiotics for long-term prevention.

Current Scientific Gaps and Research Limitations

The research describes a body of evidence marked by several limitations. The evidence quality varies across studies, with many older trials noted by systematic reviews as having a high risk of bias due to methodological issues. Furthermore, long-term effects are not fully established, as follow-up durations were limited in studies monitoring the change in recurrence frequency after the medication is discontinued. Data for certain groups, such as frail elderly patients and males with uncomplicated UTIs, remain insufficient.

Key Studies & References

1. Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: 2010 Update by IDSA
2. The Clinical Efficacy of Nitrofurantoin for Treating Uncomplicated Urinary Tract Infection in Adults

Common questions about Uvamin Retard (FAQ)

---

Q: Can Uvamin Retard be used for prevention of urinary tract infections, not just treatment?

Official information indicates that the active ingredient, nitrofurantoin, is used both for the treatment of acute urinary tract infections and for prophylaxis (prevention) against recurrent infections caused by susceptible bacteria. Official product information notes that its use may also be considered for long-term prevention.

---

Q: Are headaches a common side effect of Uvamin Retard?

Regulatory safety information classifies headache as a common side effect of Uvamin Retard. This means that, based on clinical data, this effect may be experienced by up to 1 in 10 patients taking the medication.

---

Q: Is Uvamin Retard safe to take if I have a history of liver issues?

Official drug safety information advises caution for patients with a history of hepatic function disorders (liver problems). Safety information acknowledges that there is a risk of hepatotoxicity (liver injury), and regulatory agencies note that patients should be monitored for signs of liver damage while taking it.

---

Q: Does Uvamin Retard reduce the effectiveness of birth control pills?

Yes, official drug labeling notes that the active ingredient, nitrofurantoin, may reduce the effectiveness of oestrogen-containing oral contraceptives. This potential interaction means that women taking this type of birth control pill may need to use additional contraceptive precautions during treatment.

---

Q: What are the risks of taking Uvamin Retard for a long period, such as for prevention?

Regulatory documents state that using this medication for a prolonged or chronic period is associated with an increased risk of serious adverse reactions. These include potentially irreversible conditions such as peripheral neuropathy (nerve damage) and chronic pulmonary reactions (lung problems). This is a key safety consideration for long-term use.

---

Q: Is Uvamin Retard contraindicated for people with kidney disease?

Yes, use of Uvamin Retard is contraindicated, meaning it is prohibited, for individuals with significantly impaired kidney function. This is specifically defined by regulatory bodies as a Creatinine Clearance (CrCl) of less than 60 mL/min.

---

Q: What happens if someone forgets to take one of the doses?

If a dose is missed, it should be taken as soon as it is remembered. However, official administration guidelines note that if it is nearly time for the next scheduled dose, the missed dose should be omitted and the regular schedule resumed. This prevents taking two doses too closely together.

---

Q: Can Uvamin Retard be used for UTIs in parts of the urinary tract other than the bladder?

The active ingredient is designed to reach high concentrations only in the urinary tract, resulting in minimal tissue concentration elsewhere in the body. Because of this, it is not considered suitable for systemic infections, which includes upper urinary tract infections such as pyelonephritis (a kidney infection). It is indicated only for lower urinary tract infections.

---

Q: What are the specific signs of a serious allergic reaction to Uvamin Retard?

Signs of serious hypersensitivity reactions noted in official documents include swelling of the skin and mucous membranes (such as angioedema or nettle rash). Other noted symptoms are shortness of breath and circulatory disorders. These are considered urgent signs based on regulatory safety profiles.

---

Q: How quickly do the symptoms of a UTI usually start to improve with Uvamin Retard?

Official patient guidance states that it is common for patients to feel better early in the course of therapy. However, regulatory sources emphasize that it is important to complete the full duration of the prescribed medication exactly as directed, even if symptoms subside quickly.

---

Q: Is Uvamin Retard suitable for use in men with a urinary tract infection?

The active ingredient is typically used for lower urinary tract infections. However, official regulatory guidance indicates that it has poor penetration into the prostate. Therefore, it is generally not recommended if there is a suspicion of a prostate infection (prostatitis).

---

Q: Can Uvamin Retard interfere with tests for sugar in the urine for diabetic patients?

Yes, regulatory information notes that Uvamin Retard may interfere with certain urine tests for glucose (sugar). Specifically, tests using copper sulfate solution (like Benedict's test) may result in a 'false positive' reading.

---

Q: Does Uvamin Retard contain lactose or other ingredients that people with intolerances should note?

Official labeling confirms that the medicine contains lactose among its inactive ingredients. This information is a consideration for individuals who have specific intolerances to sugars like lactose.

---

Q: How does the slow-release mechanism of Uvamin Retard help minimize side effects?

The prolonged-release design is noted to help improve gastrointestinal tolerance of the active ingredient. Gastrointestinal side effects, such as nausea, are often associated with high peak concentrations, which the slow-release formulation helps to moderate.

---

Q: Is it possible for the infection to return shortly after completing a course of Uvamin Retard?

Due to the drug's specialized action resulting in minimal tissue concentration outside the urinary tract, regulatory sources note that there is a predisposition for persistence or reappearance of bacteriuria (bacteria in the urine) after treatment.

---

Q: What should be considered when Uvamin Retard is prescribed for patients with anaemia?

Official labeling advises that the medicine should be used with caution in cases of anaemia (a decrease in red blood cells). Caution is advised because of the potential for increased risk of side effects, including peripheral neuropathy and haemolysis (red blood cell destruction), when anaemia is present.

---

Q: Is it common to experience mild diarrhea while taking Uvamin Retard?

While nausea and vomiting are classified as common side effects, regulatory data classifies diarrhea as an uncommon side effect. This means it occurs in a range of 0.1% to 1% of patients, according to regulatory data.

Storage and Disposal Requirements

Uvamin Retard (nitrofurantoin) must be stored according to specific regulatory conditions to maintain its effectiveness. The medicine must be kept out of the sight and reach of children.

Storage Conditions

Condition	Requirement (Official Labeling)
Temperature	Store at or below 30 C (86 F); do not freeze.
Protection	Protect from light and protect from moisture.
Container	Keep in the original container and ensure it is tightly closed.

Disposal Instructions

To prevent environmental contamination, official procedures require that Uvamin Retard must not be thrown away via wastewater or household waste. Any unused or expired medicine must be returned to a pharmacist for correct pharmaceutical waste disposal.